Roxro's intranasal ketorolac approved for pain in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Roxro's novel intranasal formulation of the non-steroidal anti-inflammatory drug (NSAID) ketorolac, Sprix (ketorolac tromethamine) nasal spray, for the short-term (up to five days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.